文献速递免疫规划传染病防控与疫情报告

荷兰儿童肺炎球菌结合疫苗接种十二年:对侵袭性肺炎球菌疾病发病率及临床结局的影响

Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease.
PubMed 文献 · Vaccine · 2019-09-06

该研究基于荷兰九家哨点实验室2004年6月至2018年5月住院IPD患者分离株(覆盖25%人口),分析PCV7引入前、后及PCV10替代后的IPD发病率与临床结局。结果显示,与PCV7引入前相比,2016-2018年<5岁、18-49岁和≥65岁人群IPD发病率分别下降69%、31%和19%;与PCV10引入前相比,<5岁、5-17岁和18-49岁人群IPD发病率下降,但50-64岁和≥65岁人群无显著变化。病死率从PCV前16.2%降至PCV10后13.4%,但PCV10替代对病死率无进一步影响。

要点

  • 与PCV7引入前相比,2016-2018年<5岁儿童IPD发病率下降69%。
  • PCV10替代后,<5岁、5-17岁和18-49岁人群IPD发病率下降,但≥50岁人群无显著变化。
  • 病死率从PCV前16.2%降至PCV10后13.4%,PCV10替代未进一步影响病死率。

核心结论

  • 荷兰十二年PCV接种使儿童和年轻成人IPD发病率持续下降,但PCV7换为PCV10对老年人群IPD发病率和病死率无额外影响,与新兴非疫苗血清型有关。

研究设计与样本

  • 基于荷兰九家哨点实验室(覆盖25%人口)2004年6月至2018年5月住院IPD患者肺炎球菌分离株的监测研究,所有分离株均进行血清分型。

主要发现

  • 与PCV7引入前相比,2016-2018年<5岁、18-49岁和≥65岁人群IPD发病率分别下降69%、31%和19%。
  • 与PCV10引入前相比,2016-2018年<5岁(RR:0.68,95%CI:0.42-1.11)、5-17岁(RR:0.58,95%CI:0.29-1.14)和18-49岁(RR:0.72,95%CI:0.57-0.90)人群IPD发病率下降,但50-64岁(RR:0.94,95%CI:0.81-1.10)和≥65岁(RR:1.04,95%CI:0.93-1.15)人群无显著变化。
  • 病死率从PCV前16.2%降至PCV10后13.4%(RR:0.83,95%CI:0.70-0.99),但PCV10替代对病死率无进一步影响(RR:1.14,95%CI:0.96-1.36)。

关键数值与推荐

  • 与PCV7引入前相比,2016-2018年<5岁儿童IPD发病率下降69%。
  • 与PCV10引入前相比,2016-2018年18-49岁人群IPD发病率RR为0.72(95%CI:0.57-0.90)。
  • 病死率从PCV前16.2%降至PCV10后13.4%(RR:0.83,95%CI:0.70-0.99)。

临床怎么用

  • 应持续监测IPD血清型分布以评估PCV长期效果。
  • 老年人群IPD防控需关注非疫苗血清型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2006, the Netherlands introduced the 7-valent pneumococcal conjugate vaccine (PCV7) in their national immunisation programme. In 2011, PCV7 was replaced by the 10-valent vaccine (PCV10). We report on the impact of PCV on invasive pneumococcal disease (IPD) incidence, clinical syndromes and patient outcomes. METHODS: Pneumococcal isolates of hospitalised IPD patients between June 2004 and May 2018 were obtained from nine sentinel laboratories, covering 25% of the Dutch population. All isolates were serotyped. IPD incidence and clinical outcome were determined before and after introduction of PCV7 and after the switch to PCV10, stratified by age and serotype. RESULTS: Compared to before PCV7 introduction, significant declines in IPD incidence were observed in 2016-2018 in children <5 years (69%), 18-49 year olds (31%) and ≥65 year olds (19%). Compared to before PCV10 introduction, the IPD incidence in 2016-2018 declined in children <5 years (RR:0.68, 95%CI:0.42-1.11), 5-17 year olds (RR:0.58, 95%CI:0.29-1.14) and 18-49 year olds (RR:0.72, 95%CI:0.57-0.90), but not in 50-64 year olds (RR:0.94, 95%CI:0.81-1.10) and ≥65 year olds (RR:1.04, 95%CI:0.0.93-1.15). While the case fatality rate (CFR) decreased from 16.2% pre-PCV to 13.4% post-PCV10 (RR:0.83, 95%CI:0.70-0.99), the switch to PCV10 had no further impact on CFR (RR:1.14, 95%CI:0.96-1.36). CONCLUSION: Twelve years of PCV in the Netherlands has resulted in a sustained reduction of IPD incidence in children and younger adults. The switch from PCV7 to PCV10 did not have additional impact on the IPD incidence in older adults and CFR due to emerging non-vaccine serotypes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vestjens SMT, Sanders EAM, Vlaminckx BJ, et al. Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease. Vaccine. 2019. PMID: 31500963. doi:10.1016/j.vaccine.2019.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。